MNPR
NASDAQ · Biotechnology
Monopar Therapeutics Inc
$119.23
+0.77 (+0.65%)
Open$119.00
Previous Close$118.46
Day High$120.23
Day Low$114.50
52W High$124.82
52W Low$29.18
Volume—
Avg Volume338.7K
Market Cap798.26M
P/E Ratio—
EPS$-1.90
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
-65.4% upside
Current
$119.23
$119.23
Target
$41.31
$41.31
$22.89
$41.31 avg
$45.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 251.96M | 240.93M | 249.50M |
| Net Income | -49,856,785 | -48,544,141 | -56,777,530 |
| Profit Margin | -19.8% | -20.2% | -22.8% |
| EBITDA | -96,691,861 | -80,803,710 | -82,101,366 |
| Free Cash Flow | -37,656,070 | -41,639,536 | -51,685,705 |
| Rev Growth | +2.3% | +24.0% | -9.1% |
| Debt/Equity | 0.25 | 0.23 | 0.27 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |